Overview

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Status:
Recruiting

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like. In this trial we would like to investigate whether a molecular subgroup exists within TNBCs that derives a benefit from atezolizumab added to first line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborators:

Borstkanker Onderzoek Groep
Roche Pharma AG

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Carboplatin
Cyclophosphamide
Paclitaxel